A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer

被引：3

作者：

Harada, Kazuto ^{[1
,2
]}

Abdelhakeem, Ahmed A. F. ^{[1
]}

Ajani, Jaffer A. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA

[2] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto, Japan

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2019年 / 16卷 / 01期

关键词：

LANDSCAPE;

D O I：

10.1038/s41571-018-0108-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A minority of patients with gastroesophageal adenocarcinoma derive benefit from immune-checkpoint inhibition (ICI). In a large-cohort phase III study, the nivolumab (1 mg/kg) plus ipilimumab (3 mg/kg) arm (which was based on promising preliminary data from CheckMate 032) was closed owing to unacceptably high levels of mortality and morbidity. Our quest for better biomarkers than programmed cell death 1 ligand 1 (PD-L1) and safer dual ICI strategies must continue.

引用

页码：8 / 10

页数：2

共 8 条

[1] Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Anderson, Ana C.
Joller, Nicole
Kuchroo, Vijay K.
[J]. IMMUNITY, 2016, 44 (05) : 989 - 1004
[2] FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1
Fashoyin-Aje, Lola
Donoghue, Martha
Chen, Huanyu
He, Kun
Veeraraghavan, Janaki
Goldberg, Kirsten B.
Keegan, Patricia
McKee, Amy E.
Pazdur, Richard
[J]. ONCOLOGIST, 2019, 24 (01) : 103 - 109
[3] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Hellmann, M. D.
Ciuleanu, T. -E.
Pluzanski, A.
Lee, J. S.
Otterson, G. A.
Audigier-Valette, C.
Minenza, E.
Linardou, H.
Burgers, S.
Salman, P.
Borghaei, H.
Ramalingam, S. S.
Brahmer, J.
Reck, M.
O'Byrne, K. J.
Geese, W. J.
Green, G.
Chang, H.
Szustakowski, J.
Bhagavatheeswaran, P.
Healey, D.
Fu, Y.
Nathan, F.
Paz-Ares, L.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2093 - 2104
[4] CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
Janjigian, Yelena Y.
Bendell, Johanna
Calvo, Emiliano
Kim, Joseph W.
Ascierto, Paolo A.
Sharma, Padmanee
Ott, Patrick A.
Peltola, Katriina
Jaeger, Dirk
Evans, Jeffry
de Braud, Filippo
Chau, Ian
Harbison, Christopher T.
Dorange, Cecile
Tschaika, Marina
Le, Dung T.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) : 2836 - +
[5] Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Kang, Yoon-Koo
Boku, Narikazu
Satoh, Taroh
Ryu, Min-Hee
Chao, Yee
Kato, Ken
Chung, Hyun Cheol
Chen, Jen-Shi
Muro, Kei
Kang, Won Ki
Yeh, Kun-Huei
Yoshikawa, Takaki
Oh, Sang Cheul
Bai, Li-Yuan
Tamura, Takao
Lee, Keun-Wook
Hamamoto, Yasuo
Kim, Jong Gwang
Chin, Keisho
Oh, Do-Youn
Minashi, Keiko
Cho, Jae Yong
Tsuda, Masahiro
Chen, Li-Tzong
[J]. LANCET, 2017, 390 (10111) : 2461 - 2471
[6] Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Shitara, Kohei
Ozguroglu, Mustafa
Bang, Yung-Jue
Di Bartolomeo, Maria
Mandala, Mario
Ryu, Min-Hee
Fornaro, Lorenzo
Olesinski, Tomasz
Caglevic, Christian
Chung, Hyun C.
Muro, Kei
Goekkurt, Eray
Mansoor, Wasat
McDermott, Raymond S.
Shacham-Shmueli, Einat
Chen, Xinqun
Mayo, Carlos
Kang, S. Peter
Ohtsu, Atsushi
Fuchs, Charles S.
[J]. LANCET, 2018, 392 (10142) : 123 - 133
[7] Thorsson V, 2019, IMMUNITY, V51, P411, DOI [10.1016/j.immuni.2019.08.004, 10.1016/j.immuni.2018.03.023]
[8] Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Zehir, Ahmet
Benayed, Ryma
Shah, Ronak H.
Syed, Aijazuddin
Middha, Sumit
Kim, Hyunjae R.
Srinivasan, Preethi
Gao, Jianjiong
Chakravarty, Debyani
Devlin, Sean M.
Hellmann, Matthew D.
Barron, David A.
Schram, Alison M.
Hameed, Meera
Dogan, Snjezana
Ross, Dara S.
Hechtman, Jaclyn F.
DeLair, Deborah F.
Yao, JinJuan
Mandelker, Diana L.
Cheng, Donavan T.
Chandramohan, Raghu
Mohanty, Abhinita S.
Ptashkin, Ryan N.
Jayakumaran, Gowtham
Prasad, Meera
Syed, Mustafa H.
Rema, Anoop Balakrishnan
Liu, Zhen Y.
Nafa, Khedoudja
Borsu, Laetitia
Sadowska, Justyna
Casanova, Jacklyn
Bacares, Ruben
Kiecka, Iwona J.
Razumova, Anna
Son, Julie B.
Stewart, Lisa
Baldi, Tessara
Mullaney, Kerry A.
Al-Ahmadie, Hikmat
Vakiani, Efsevia
Abeshouse, Adam A.
Penson, Alexander V.
Jonsson, Philip
Camacho, Niedzica
Chang, Matthew T.
Won, Helen H.
Gross, Benjamin E.
Kundra, Ritika
[J]. NATURE MEDICINE, 2017, 23 (06) : 703 - +

← 1 →